Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
about
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.Managing multiple myeloma in elderly patients.Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.Treatment of newly diagnosed myeloma: Bortezomib-based triplet.Safety of ixazomib for the treatment of multiple myeloma.Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.Emerging drugs and combinations to treat multiple myeloma.Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter.Therapy sequencing strategies in multiple myeloma: who, what and why?Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.The proteasome and proteasome inhibitors in multiple myeloma.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.Triplet vs. doublet drug regimens for managing multiple myeloma.Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma.Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.New agents in the Treatment of Myeloma Bone Disease.Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.Prognostic significance of the red blood cell distribution width that maintain at high level following completion of first line therapy in mutiple myeloma patients.Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.The evolution of stem-cell transplantation in multiple myeloma.Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.Short overview on the current standard of treatment in newly diagnosed multiple myeloma.Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.Multiple myelomaMultiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementBortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myelomaAbducens Nerve Palsy as Initial Presentation of Multiple Myeloma and Intracranial PlasmacytomaA phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
P2860
Q33442923-844C3847-6B8A-4967-B406-75CF06889811Q38375972-2B73B05D-F8FB-48CB-8D05-6858E49C9D46Q38605484-E45567C4-5BC6-430A-AD7C-FDDEB26BBD89Q38627306-9DFE6890-1F63-426B-AAE8-8022BE5E4F1DQ38691698-1C39A20F-C077-4FCF-AEEE-FDF655CCAE10Q39035350-026E6FC8-27A3-447D-AD3D-5A30CB6BA830Q39404809-AAA99D9E-D5E3-43DC-97E2-1410721A7D61Q41545464-90C4AAA9-EA82-4587-AA74-F57377034F54Q41694198-2493C972-F6B1-4FFD-9ECB-46A14D92155AQ42150701-3CE3BFBA-EA71-4EBD-8FB5-77A305623D60Q45946305-F0EAF6FA-41E1-453D-B255-5BBE1E9698B6Q47207279-BBEDCDFD-DAF7-49F4-B545-CB031ED881F3Q47339695-AA10DF94-609D-4A56-8CCF-8BD2FE73F02AQ47418005-70BBE631-C5E1-4F1F-84ED-AAC4774320DDQ47562378-E71DF89A-DA6D-46DE-84F9-3890C3CA4290Q47770089-FF547B1E-1DF5-402D-A893-076E149DCA36Q47775860-3243F2E7-9B90-4CEB-B9EB-9E04096625E1Q48150171-32FF7219-4436-4B87-A69C-AE148A797D19Q49761601-FF4188CD-C26B-46D6-9C60-99C10F995535Q50323850-C36DAF86-A5B2-4ED4-859E-1C2A72B47D1EQ50589659-6836DC0B-038E-4607-8A33-DB455F38298FQ52668165-79BDE251-82F5-4DC0-B10D-D2E51A4627A1Q52686509-11E3EBFA-7DDF-4208-9167-42DF424D6DBEQ52715329-036D851E-4DE7-43B1-B744-EC43A462D84FQ54986945-2AE82062-9AF5-4A2F-ABF3-6965960E27F1Q55091245-98CD0903-C412-4176-A69F-38D3C06040DEQ55119916-5835E80A-CD20-494E-ACFE-17E3EB3D44AEQ55359383-FA2D72A1-E7AD-496F-9848-99E895883238Q56657250-9B8B2877-2C82-4DC6-A233-02F7D6F70AEEQ58565204-988F2364-A204-4A21-B59A-351F94680EF2Q58575863-945D604A-AE0A-4203-A001-D0929E43A42FQ58766553-9DEB2B10-C054-4FBE-A575-5C729FCD5A6AQ58776948-26116D2F-95A7-4DEA-8F43-AABB52FE68F4
P2860
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Bortezomib with lenalidomide a ...... ed, open-label, phase 3 trial.
@en
Bortezomib with lenalidomide a ...... ed, open-label, phase 3 trial.
@nl
type
label
Bortezomib with lenalidomide a ...... ed, open-label, phase 3 trial.
@en
Bortezomib with lenalidomide a ...... ed, open-label, phase 3 trial.
@nl
prefLabel
Bortezomib with lenalidomide a ...... ed, open-label, phase 3 trial.
@en
Bortezomib with lenalidomide a ...... ed, open-label, phase 3 trial.
@nl
P2093
P2860
P50
P1433
P1476
Bortezomib with lenalidomide a ...... ed, open-label, phase 3 trial.
@en
P2093
Brian G M Durie
Christopher M Reynolds
Frederic Reu
Joshua Epstein
Mohan Thakuri
Muneer H Abidi
Rachael Sexton
Stephen P Kahanic
P2860
P304
P356
10.1016/S0140-6736(16)31594-X
P407
P577
2016-12-22T00:00:00Z